title: Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
abstract: Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently developing an orphan drug framework, in the United States (US), the Orphan Drug Act (ODA) of 1983 established incentives for the development of orphan drugs. This study measured total annual expenditure of orphan drugs in Canada (2007-13) and estimated future (2014-18) orphan drug expenditure.
  
  
  
  Orphan drugs approved by the US Food and Drug Administration (FDA) in the US were used as a proxy for the orphan drug landscape in Canada. Branded, orphan drugs approved by the FDA between 1983 through 2013 were identified (N = 356 unique products). Only US orphan drugs with the same orphan indication(s) approved in Canada were included in the analysis. Adjustment via an indication factoring was applied to products with both orphan and non-orphan indications using available data sources to isolate orphan-indication sales. The IMS Health MIDAS database of audited biopharmaceutical sales was utilized to measure total orphan drug expenditure, calculated annually from 2007-2013 and evaluated as a proportion of total annual pharmaceutical drug expenditure (adjusted to 2014 CAD).
  
  
  
  Between 2007 and 2013, expenditure was measured for a final N = 147 orphan drugs. Orphan drug expenditure totaled $610.2 million (M) in 2007 and $1,100.0 M in 2013, representing 3.3- 5.6 % of total Canadian pharmaceutical drug expenditure in 2007-2013, respectively. Future trend analysis suggests orphan drug expenditure will remain under 6 % of total expenditure in 2014-18.
  
  
  
  While the number of available orphan drugs and associated expenditure increased over time, access remains an issue, and from the perspectives of society and equity, overall spending on orphan drugs is lower relative to the number of patients affected with an orphan disease in Canada. The overall budget impact of orphan drugs is small and fairly stable relative to total pharmaceutical expenditure. Concerns that growth in orphan drug expenditure may lead to unsustainable drug expenditure do not appear to be justified.
authors.affiliation: IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA. vdivino@us.imshealth.com.
authors.forename: Victoria
authors.initials: V
authors.lastname: Divino
authors.affiliation: IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA.
authors.forename: Mitch
authors.initials: M
authors.lastname: DeKoven
authors.affiliation: IMS Institute for Healthcare Informatics, One IMS Drive, Plymouth Meeting, PA, 19462, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Kleinrock
authors.affiliation: IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA.
authors.forename: Rolin L
authors.initials: RL
authors.lastname: Wade
authors.affiliation: Celgene, 6755 Mississauga Rd, Suite 600, Mississauga, ON, L5N 7Y2, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Kim
authors.affiliation: Celgene, 86 Morris Avenue, H-222H, Summit, NJ, 07901, USA.
authors.forename: Satyin
authors.initials: S
authors.lastname: Kaura
mesh_terms: D002170:Canada; D005102:Health Expenditures / Q000706:statistics & numerical data*; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy / Q000191:economics*
keywords: Cost of health care; Health economics; Health spending; Orphan drugs; Pharmaceuticals; Rare diseases